Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Summary

This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.

Interventions

• RMC-9805 · DRUG

  Oral Tablets

• RMC-6236 · DRUG

  Oral Tablets

Published eligibility criteria

Verbatim from the registry. Only the site can decide how these apply to a specific patient.

Inclusion Criteria:

* Pathologically documented, locally advanced or metastatic solid tumor with a KRAS G12D-mutation
* Received and progressed or been intolerant to prior standard therapy (including targeted therapy) appropriate for tumor type and stage
* ECOG performance status 0 or 1
* Adequate organ function

Exclusion Criteria:

* Primary central nervous system (CNS) tumors
* Known or suspected leptomeningeal or active brain metastases or spinal cord compression
* Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication
* Participant was previously treated with an investigational KRAS G12D inhibitor, pan- or multi-RAS inhibitor, or had prior therapy with any direct RAS-targeted therapy (eg, degraders and inhibitors)

Other inclusion/exclusion criteria may apply.

Sites (17)

• University of California, Davis Comprehensive Cancer Center, Sacramento, California · RECRUITING
• Smilow Cancer Hospital (Yale University), New Haven, Connecticut · RECRUITING
• Florida Cancer Specialists, Sarasota, Florida · RECRUITING
• Lee Moffitt Cancer Center, Tampa, Florida · RECRUITING
• Johns Hopkins University, Baltimore, Maryland · RECRUITING
• Massachusetts General Hospital, Boston, Massachusetts · RECRUITING
• Dana-Farber Cancer Institute, Boston, Massachusetts · RECRUITING
• NYU Langone, New York, New York · RECRUITING
• Memorial Sloan Kettering Cancer Center, New York, New York · RECRUITING
• Duke Cancer Center, Durham, North Carolina · RECRUITING
• Carolina BioOncology Institute, Huntersville, North Carolina · RECRUITING
• The Christ Hospital, Cincinnati, Ohio · RECRUITING
• Sarah Cannon Research Institute, Nashville, Tennessee · RECRUITING
• Sarah Cannon Research Institute at Mary Crowley, Dallas, Texas · RECRUITING
• University of Texas, MD Anderson Cancer Center, Houston, Texas · RECRUITING
• START, San Antonio, Texas · RECRUITING
• NEXT Oncology Virginia, Fairfax, Virginia · RECRUITING